Follow me on Twitter

I agree that content from Twitter will be displayed to me.

 

Postdoc

Claire completed her PhD in 2011 at the Pasteur Institute in Paris, France and worked for two years as a postdoctoral scientist at the Institut de Chimie des Substances Naturelles at Gif-sur-Yvette, France. Since 2013, her research has been focused on the structural characterization of Solute Carrier (SLC) transporters. In humans, there are over 450 SLCs that transport a broad range of substrates, including neurotransmitters, metabolites, and drugs. Thus, SLCs are emerging as important therapeutic targets. First at the mount Sinai School of Medicine in New-York City (2013-2018) and then in Vienna (2018-present), Claire has been working on six distinct SLC families, involved in various diseases and disorders. She uses various computational methods such as homology modeling and molecular docking to explore the structural determinants defining the substrate specificities of SLCs.

Publications

Showing entries 1 - 5 out of 28
Dvorak V, Casiraghi A, Colas C, Koren A, Tomek T, Offensperger F et al. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell Chemical Biology. 2023 Aug 17;30(8):953-964.e9. doi: 10.1016/j.chembiol.2023.06.029

Niello M, Cintulová D, Raithmayr P, Holy M, Jäntsch K, Colas C et al. Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity in vitro. Frontiers in Pharmacology. 2021 Apr 9;12:654061. doi: 10.3389/fphar.2021.654061

Colas C, Laine E. Targeting Solute Carrier Transporters through Functional Mapping. Trends in Pharmacological Sciences. 2021 Jan 1;42(1):3-6. Epub 2020 Nov 21. doi: 10.1016/j.tips.2020.11.005

Cosco J, Scalise M, Colas C, Galluccio M, Martini R, Rovella F et al. ATP modulates SLC7A5 (LAT1) synergistically with cholesterol. Scientific Reports. 2020 Oct 7;10(1):16738. 16738. doi: 10.1038/s41598-020-73757-y